2153
Study 202 was an open-label, add-on study in patients with partial or generalized epilepsy treated with valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), or topiramate (TPM) as monotherapy.
 patients with partial or generalized epilepsy: Subject; valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), or topiramate (TPM) as monotherapy: Treatment; valproic acid: Treatment.Drug; carbamazepine: Treatment.Drug; phenytoin: Treatment.Drug; topiramate: Treatment.Drug; valproic acid: Combination.Drug; carbamazepine: Combination.Drug; phenytoin: Combination.Drug; topiramate: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients with partial or generalized epilepsy: Subject; valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), or topiramate (TPM) as monotherapy: Treatment; valproic acid: Treatment.Drug; carbamazepine: Treatment.Drug; phenytoin: Treatment.Drug; topiramate: Treatment.Drug; valproic acid: Combination.Drug; carbamazepine: Combination.Drug; phenytoin: Combination.Drug; topiramate: Combination.Drug